Program
pegozafermin
Also written as “Pegozafermin” and “BIO89-100”.
Its studies are mostly in Non-alcoholic Fatty Liver Disease · Hypertriglyceridemia, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| 89bio | 50 open or running | phase 3since May 2, 2023 | Aug 4, 2019 | none ahead |
| Hoffmann-La Roche | 33 open or running | phase 3since Mar 13, 2024 | Mar 13, 2024 | Mar 2, 2027phase 1 · NCT07835243 |
- Named in Hoffmann-La Roche’s own pipeline as
RG6881 pegozafermin
, phase 3, as of Oct 22, 2026 (source).
Also a collaborator on its studies: prosciento-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 4, 2019First study: phase 2 study in Non-alcoholic Fatty Liver DiseaseNew to 89bio89bio · NCT04048135 · 101 enrolled · United States, Puerto Rico
- Aug 14, 2020Phase 2 study in Hypertriglyceridemia89bio · NCT04541186 · 86 enrolled · United States, Czechia, Hungary and more
- Jun 10, 2021Phase 2 study in Non-alcoholic Fatty Liver Disease89bio · NCT04929483 · 222 enrolled · United States, Puerto Rico
- Aug 20, 2021Phase 1 study in Non-alcoholic Fatty Liver Disease89bio · NCT05022693 · 8 enrolled · United States
- May 2, 2023Phase 3 study in Hypertriglyceridemia89bio · NCT05852431 · 369 enrolled · United States, Argentina, Austria and more
- Mar 13, 2024Hoffmann-La Roche's first study: phase 3 study in Non-alcoholic Fatty Liver DiseaseNew to Hoffmann-La RocheHoffmann-La Roche · NCT06318169 · 1,350 planned · United States, Argentina, Australia and more
- May 14, 2024Phase 3 study in Non-alcoholic Fatty Liver DiseaseHoffmann-La Roche · NCT06419374 · 1,800 planned · United States, Argentina, Australia and more
- Sep 17, 2026Phase 1 study in Healthy VolunteersHoffmann-La Roche · NCT07835243 · 105 planned
Ahead
- Mar 2, 2027Primary completion: phase 1 study in Healthy VolunteersHoffmann-La Roche · NCT07835243
- Jun 30, 2028Primary completion: phase 3 study in Non-alcoholic Fatty Liver DiseaseHoffmann-La Roche · NCT06419374
- Feb 2029Primary completion: phase 3 study in Non-alcoholic Fatty Liver DiseaseHoffmann-La Roche · NCT06318169
TargetBeta
“A glycopegylated form of fibroblast growth factor 21 (FGF21), with metabolic regulating, anti-diabetic, anti-lipidemic, and anti-fibrotic activities. Upon administration, pegozafermin mimics FGF21, and binds to FGF21-specific receptors, FGFR1c, FGFR2c, and FGFR3c, in the liver and adipose tissue.…”NCIt, read by Claude
Other programs on FGF21
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| efimosfermin alfa | GlaxoSmithKline | phase 3 | 10 |
| efruxifermin | Novo Nordisk | phase 3 | 6 |
| zalfermin | Novo Nordisk | phase 2 | 10 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07835243Healthy Volunteers | 1 | Not yet recruiting | Hoffmann-La Roche | Mar 2, 2027 | 105 |
| NCT06419374Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more | 3 | Recruiting | Hoffmann-La Roche | Jun 30, 2028 | 1,800 |
| NCT06318169Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more | 3 | Recruiting | Hoffmann-La Roche | Feb 2029 | 1,350 |
| NCT05852431Hypertriglyceridemia · United States, Argentina, Austria and more | 3 | Completed | 89bio | Jul 7, 2025 | 369 |
| NCT05022693Non-alcoholic Fatty Liver Disease · United States | 1 | Completed | 89bio | Dec 21, 2021 | 8 |
| NCT04929483Non-alcoholic Fatty Liver Disease · United States, Puerto Rico | 2 | Completed | 89bio | Feb 14, 2023 | 222 |
| NCT04541186Hypertriglyceridemia · United States, Czechia, Hungary and more | 2 | Completed | 89bio | May 19, 2022 | 86 |
| NCT04048135Non-alcoholic Fatty Liver Disease · United States, Puerto Rico | 2 | Completed | 89bio | Aug 28, 2020 | 101 |
How it is read
Names in the registry
- “Pegozafermin”, 6 entries
- “BIO89-100”, 2 entries
Conditions, from the studies’ own filings
- Non-alcoholic Fatty Liver Disease, 5 studies
- Hypertriglyceridemia, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.